Advanced Solutions
for Advanced Pathology
NSE (MRQ-55)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45243 IMPATH NSE RTU M (MRQ-55)
50 Tests
44353 NSE RTU M (MRQ-55)
7 ml Ready To Use
44726 NSE 0,1 M (MRQ-55)
100 µl liquid Concentrated
44727 NSE 1 M (MRQ-55)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic
Control
Carcinoid tumor, Pancreas
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
2b
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP 2-step
Polymer (Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
Neuron-specific enolase (NSE) is the glycolytic isoenzyme of the enolase gamma-gamma dimer specifically detected in neurons of
neuroendocrine cells, and their corresponding tumors. In addition, NSE has been demonstrated immunohistochemically in the non-neoplastic
cells of the pituitary, peptide secreting tissues, pineolocytes, neuroendocrine cells of the lung, thyroid, parafollicular cells, adrenal medulla, islets
of Langerhans, Merkel cells of the skin, and melanocytes. Anti-NSE immunostaining is also positive in normal striated muscle, hepatocytes and,
to a lesser extent, smooth muscle. Anti-NSE is a useful marker to identify peripheral nerves. When used for the identification of neuroendocrine
differentiation, it is necessary that it be employed in a panel with more specific markers such as anti-synaptophysin, anti-chromogranin, and
anti-neurofilament.
Retroperitoneal Lesions
NSE
Synapto-
physin
Chromo-
granin A
Neuro-
filament
PGP 9.5
S-100
GFAP
CD99
Neuroblastoma
+
+
+
+
+
-
-
-
Ganglioneuroblastoma
+
+
+
+
+
+
+
-
Ganglioneuroma
+
+
+
+
+
+
+
-
Leiomyosarcoma
-/+
-
-
-
-/+
-
-
-
Rhabdomyosarcoma
-
-
-
-
+
-
-
-
Synovial Sarcoma
-
-
-
-
-/+
-
+/-
Reference
1. Wick MR, et al. American Journal of Clinical Pathology. 1983; 29:703-7.
2. Venores SA, et al. Archives of Pathology and Laboratory Medicine. 1984; 108:536-40.
3. Leong AS-Y, et al. Pathology. 1986; 18:393-9.
4. Cooper EH. International Journal of Biological Markers. 1994; 9:205-10.
5. Loenard N, et al. Gut. 1995; 37:763-5.
183
